EP1080113A4 - Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance - Google Patents
Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissanceInfo
- Publication number
- EP1080113A4 EP1080113A4 EP99924253A EP99924253A EP1080113A4 EP 1080113 A4 EP1080113 A4 EP 1080113A4 EP 99924253 A EP99924253 A EP 99924253A EP 99924253 A EP99924253 A EP 99924253A EP 1080113 A4 EP1080113 A4 EP 1080113A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- inhibitors
- radiation
- treatment
- growth factor
- factor receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US206138 | 1988-06-13 | ||
US7961298A | 1998-05-15 | 1998-05-15 | |
US8561398P | 1998-05-15 | 1998-05-15 | |
US85613P | 1998-05-15 | ||
US79612 | 1998-05-15 | ||
US20613898A | 1998-12-07 | 1998-12-07 | |
PCT/US1999/010741 WO1999060023A1 (fr) | 1998-05-15 | 1999-05-14 | Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1080113A1 EP1080113A1 (fr) | 2001-03-07 |
EP1080113A4 true EP1080113A4 (fr) | 2002-04-17 |
Family
ID=27373511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99924253A Withdrawn EP1080113A4 (fr) | 1998-05-15 | 1999-05-14 | Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1080113A4 (fr) |
JP (1) | JP2002515511A (fr) |
KR (1) | KR20010071271A (fr) |
CN (1) | CN1314917A (fr) |
AU (1) | AU4079999A (fr) |
BR (1) | BR9910511A (fr) |
CA (1) | CA2332331A1 (fr) |
CZ (1) | CZ20004224A3 (fr) |
HK (1) | HK1040720A1 (fr) |
IL (1) | IL139707A0 (fr) |
MX (1) | MXPA00011248A (fr) |
PL (1) | PL348634A1 (fr) |
SK (1) | SK17282000A3 (fr) |
WO (1) | WO1999060023A1 (fr) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
EP1745799B1 (fr) | 1998-03-04 | 2015-09-02 | The Trustees of The University of Pennsylvania | Compositions et méthodes pour le traitement de tumeurs |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
JP2003503313A (ja) | 1999-06-03 | 2003-01-28 | ジェシー エル エス オウ | 細胞増殖及び細胞死を変調する方法及び組成物 |
GB9925958D0 (en) * | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
JP2004527456A (ja) * | 2000-08-09 | 2004-09-09 | イムクローン システムズ インコーポレイティド | Egf受容体拮抗剤による過増殖性の疾患の治療 |
AU2002239486A1 (en) * | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
CU22979A1 (es) * | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
CA2478169C (fr) | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Anticorps humains specifiques de kdr et leurs utilisations |
ES2299692T3 (es) * | 2002-04-02 | 2008-06-01 | Nerviano Medical Sciences S.R.L. | Terapia combinada contra tumores que comprende derivados de distmicina acriloil sustituido y radioterapia. |
NZ571508A (en) | 2002-05-24 | 2010-05-28 | Schering Corp | Neutralizing human anti-IGFR antibody |
EP1622942B1 (fr) | 2003-05-01 | 2014-11-19 | ImClone LLC | Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline |
CN101966338A (zh) | 2003-06-09 | 2011-02-09 | 塞缪尔·瓦克萨尔 | 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法 |
US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
MXPA06001634A (es) | 2003-08-13 | 2006-04-28 | Pfizer Prod Inc | Anticuerpos humanos modificados igf-1r. |
WO2005047512A2 (fr) | 2003-11-12 | 2005-05-26 | Shering Corporation | Systeme de plasmide pour l'expression multigenique |
TW200526684A (en) | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
JP4734319B2 (ja) | 2004-03-19 | 2011-07-27 | イムクローン・リミテッド・ライアビリティ・カンパニー | ヒト抗上皮成長因子受容体抗体 |
CN1968706A (zh) | 2004-06-03 | 2007-05-23 | 霍夫曼-拉罗奇有限公司 | 用顺铂和egfr-抑制剂治疗 |
US7811562B2 (en) | 2004-12-03 | 2010-10-12 | Schering Corporation | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US8128929B2 (en) | 2005-06-17 | 2012-03-06 | Imclone Llc | Antibodies against PDGFRa |
ES2374450T3 (es) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
CA2625440C (fr) | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
NZ574580A (en) | 2006-08-21 | 2011-12-22 | Hoffmann La Roche | Her2 tumor therapy with an anti-vegf antibody |
SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
CA2682626A1 (fr) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Elements de liaison bispecifiques specifiques d'especes croisees |
WO2009030368A1 (fr) | 2007-09-05 | 2009-03-12 | F. Hoffmann-La Roche Ag | Polythérapie avec des anticorps anti-cd20 de type i et de type ii |
US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
US8623592B2 (en) | 2008-08-15 | 2014-01-07 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
EP2408479A1 (fr) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Plurithérapie contre le cancer comprenant l'administration d'un inhibiteur de l'egfr et d'un inhibiteur de l'igf-1r |
ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
EP2236139A1 (fr) | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Thérapie combinée d'erlotinibe avec un anticorps anti-IGF-1R, qui n'inhibe pas la liaison d'insuline dans le récepteur d'insuline |
US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法 |
CA2769595A1 (fr) | 2009-08-14 | 2011-02-17 | Roche Glycart Ag | Polytherapie a base d'un anticorps afucosyle anti-cd20 et de fludarabine et/ou mitoxantrone |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2519826A2 (fr) | 2010-03-03 | 2012-11-07 | OSI Pharmaceuticals, LLC | Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1 |
EA201201186A1 (ru) | 2010-03-11 | 2013-11-29 | Мерримак Фармасьютикалс, Инк. | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
EP2563391B1 (fr) | 2010-04-27 | 2020-08-26 | Roche Glycart AG | Polythérapie d'un anticorps CD20 afucosylaté avec un inhibiteur mTOR |
TW201208703A (en) | 2010-08-17 | 2012-03-01 | Roche Glycart Ag | Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
WO2012080389A1 (fr) | 2010-12-16 | 2012-06-21 | Roche Glycart Ag | Thérapie d'association d'un anticorps cd20 afucosylé avec un inhibiteur mdm2 |
EP2671082B1 (fr) | 2011-02-02 | 2020-01-15 | Amgen Inc. | Méthodes et compositions associées à l'inhibition d'igf-1r |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
WO2012129145A1 (fr) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Polythérapie du cancer du poumon non à petites cellules (nsclc) |
US8628773B2 (en) | 2011-04-07 | 2014-01-14 | Amgen Inc. | Antigen binding proteins |
WO2012149014A1 (fr) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer |
EP2776042B1 (fr) | 2011-11-11 | 2019-03-20 | Duke University | Polythérapie médicamenteuse pour le traitement de tumeurs solides |
US20130302274A1 (en) | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
JP6207531B2 (ja) * | 2012-02-23 | 2017-10-04 | ダイイチサンキョウヨーロッパ ゲーエムベーハー | 放射線感受性を調節するためのher3阻害剤 |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
WO2013152252A1 (fr) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Polythérapie antinéoplasique |
JP6408993B2 (ja) | 2012-09-07 | 2018-10-17 | ジェネンテック, インコーポレイテッド | タイプII抗CD20抗体と選択的Bcl−2インヒビターの併用療法 |
US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
EP3087394A2 (fr) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies |
RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
SI3319995T1 (sl) | 2015-07-07 | 2019-07-31 | F. Hoffmann-La Roche Ag | Kombinirana terapija s konjugatom protitelo anti-HER-2 in zdravilo ter zaviralcem bcl-2 |
CA3006743A1 (fr) | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Inhibiteurs de mat2a pour le traitement du cancer n'exprimant pas mtap |
EP3405194A1 (fr) | 2016-01-18 | 2018-11-28 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Utilisation d'un inhibiteur temporaire de p53 à des fins de prévention ou de réduction des rechutes de cancer |
WO2017205465A2 (fr) | 2016-05-24 | 2017-11-30 | Griswold Karl Edwin | Anticorps et leurs procédés de production |
JP2020528418A (ja) | 2017-07-26 | 2020-09-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | BET阻害剤及びBcl−2阻害剤を用いた併用療法 |
CN110869391A (zh) | 2017-07-26 | 2020-03-06 | 豪夫迈·罗氏有限公司 | 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法 |
TW201920282A (zh) * | 2017-09-29 | 2019-06-01 | 中國大陸商上海藥明生物技術有限公司 | 抗egfr和pd-1的雙特異性抗體 |
WO2019201882A1 (fr) | 2018-04-18 | 2019-10-24 | F. Hoffmann-La Roche Ag | Polythérapie avec un inhibiteur de bet et un inhibiteur du protéasome |
WO2020234445A1 (fr) | 2019-05-23 | 2020-11-26 | F. Hoffmann-La Roche Ag | Polythérapie avec un inhibiteur de bet et un inhibiteur de bcl-2 |
WO2021155006A1 (fr) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040210A1 (fr) * | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Anticorps et fragments d'anticorps inhibant la croissance des tumeurs |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
-
1999
- 1999-05-14 CA CA002332331A patent/CA2332331A1/fr not_active Abandoned
- 1999-05-14 MX MXPA00011248A patent/MXPA00011248A/es unknown
- 1999-05-14 BR BR9910511-0A patent/BR9910511A/pt not_active Application Discontinuation
- 1999-05-14 AU AU40799/99A patent/AU4079999A/en not_active Abandoned
- 1999-05-14 CN CN99808614A patent/CN1314917A/zh active Pending
- 1999-05-14 JP JP2000549641A patent/JP2002515511A/ja active Pending
- 1999-05-14 SK SK1728-2000A patent/SK17282000A3/sk unknown
- 1999-05-14 CZ CZ20004224A patent/CZ20004224A3/cs unknown
- 1999-05-14 KR KR1020007012832A patent/KR20010071271A/ko not_active Application Discontinuation
- 1999-05-14 IL IL13970799A patent/IL139707A0/xx unknown
- 1999-05-14 PL PL99348634A patent/PL348634A1/xx unknown
- 1999-05-14 EP EP99924253A patent/EP1080113A4/fr not_active Withdrawn
- 1999-05-14 WO PCT/US1999/010741 patent/WO1999060023A1/fr not_active Application Discontinuation
-
2002
- 2002-03-18 HK HK02102068.1A patent/HK1040720A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040210A1 (fr) * | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Anticorps et fragments d'anticorps inhibant la croissance des tumeurs |
Non-Patent Citations (5)
Title |
---|
BALABAN NAOMI ET AL: "The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1314, no. 1-2, 1996, pages 147 - 156, XP001055207, ISSN: 0006-3002 * |
GOLDKORN T ET AL: "EGF receptor phosphorylation is affected by ionizing radiation", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1358, no. 3, 11 October 1997 (1997-10-11), pages 289 - 299, XP004277704, ISSN: 0167-4889 * |
SALEH M ET AL: "In vitro and in vivo evaluation of the cytotoxicity of radiation combined with chimeric monoclonal antibody to the epidermal growth factor receptor.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 37, 1996, 87th Annual Meeting of the American Association for Cancer Research;Washington, D.C., USA; April 20-24, 1996, 1996, pages 612, XP001027768, ISSN: 0197-016X * |
SALEH MANSOOR N ET AL: "Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 14, no. 6, 1999, pages 451 - 463, XP001027767, ISSN: 1084-9785 * |
See also references of WO9960023A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU4079999A (en) | 1999-12-06 |
PL348634A1 (en) | 2002-06-03 |
WO1999060023A1 (fr) | 1999-11-25 |
CA2332331A1 (fr) | 1999-11-25 |
KR20010071271A (ko) | 2001-07-28 |
JP2002515511A (ja) | 2002-05-28 |
EP1080113A1 (fr) | 2001-03-07 |
MXPA00011248A (es) | 2004-09-06 |
SK17282000A3 (sk) | 2002-04-04 |
BR9910511A (pt) | 2001-11-20 |
HK1040720A1 (zh) | 2002-06-21 |
CN1314917A (zh) | 2001-09-26 |
CZ20004224A3 (cs) | 2002-02-13 |
IL139707A0 (en) | 2002-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL139707A0 (en) | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases | |
EP1218032A4 (fr) | Traitement de tumeurs humaines refractaires avec des antagonistes de recepteurs du facteur de croissance epidermique | |
IL134013A (en) | Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors | |
HUP9904361A3 (en) | Use of isobutylgaba and its derivatives for the treatment of pain | |
MD960217A (en) | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | |
EP1073496A4 (fr) | Catheter d'irradiation ameliore et procede d'utilisation | |
IL126768A0 (en) | Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy | |
HUP0203035A3 (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
DE60014581D1 (de) | Dynamische kühlung von hautgewebe zur strahlungsbehandlung | |
EP1097165A4 (fr) | Nouveaux inhibiteurs de l'angiogenese et de la croissance tumorale | |
AU8397998A (en) | Method and apparatus for radiation and hyperthermia therapy of tumors | |
AU6528800A (en) | Methods and apparatuses for radiation treatment | |
HK1025327A1 (en) | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia | |
EP1169319A4 (fr) | Procedes et compositions permettant la degradation et/ou l'inhibition des tyrosine kinases appartenant a la famille her | |
HK1043113A1 (zh) | 端粒酶抑制劑及其使用方法 | |
DE60030164D1 (de) | 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie | |
EP1054979A4 (fr) | Compositions et procedes servant a sensibiliser et a inhiber la croissance de cellules cancereuses humaines | |
GB9811598D0 (en) | Diagnosis and treatment of cancer | |
HK1046915A1 (zh) | 人類肝細胞生長因子受體酪氨酸激酶催化結構域及鑒定其抑制劑的方法 | |
EP1181374A4 (fr) | Nouvelles kinases humaines et murines | |
EP1161451A4 (fr) | Endokine alpha humain et methodes d'utilisation | |
IL153769A0 (en) | Methods of treating cancer and the pain associated therewith using endothelin antagonists | |
NO20021430L (no) | Fremgangsmåte for terapeutisk forvaltning av ekstrauterin proliferering av endometrievev, kronisk bekkensmerte ogegglederobstruksjon | |
AU2002366230A1 (en) | Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation | |
IL132531A0 (en) | Detection and therapy of tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001215 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BUCHSBAUM, DONALD, JAY Inventor name: ROBERT, FRANCISCO Inventor name: SALEH, MANSOOR, N. Inventor name: WAKSAL, HARLAN, W. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020301 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07K 16/00 A, 7A 61K 39/395 B, 7A 61N 5/10 B, 7C 07K 16/28 B |
|
TPAD | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOS TIPA |
|
17Q | First examination report despatched |
Effective date: 20030114 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050531 |